Canadian company CB2 Insights has announced a prospective trial to the safety, efficacy and other health measures for patients looking to treat anxiety.
It will undertake the trial with GL Brands through its US-based
hemp brand and key operating subsidiary, Green Lotus.
The study will use Green Lotus’ cannabidiol soft gel
Prad Sekar, CEO of CB2 Insights, said: “We are proud to have been approached by GL Brands to help advance their product research and development efforts using our vast network of clinical sites and knowledge and experience in conducting clinical trials.
“Cannabis licensed producers, product manufacturers and
cannabis-focused pharmaceutical companies have all matured to the point of
needing clinically-driven research to support the registration of their medical
“Our tools and experience help formalise and expedite that process in a way that is aligned with traditional pharmaceutical products.”
Patients and clinicians will be recruited for the study
through the existing CB2 Insights clinical network which represents the largest
medical cannabis patient registry in the US, a press release states.
The trial will incorporate a multi-centre experimental
pre-test, post-test, non-randomised design and will monitor patients using the
specified Green Lotus treatment over a 90-day period.
“Through our subsidiary brand, Green Lotus, we have brought
to market one of the most wide-ranging lines of natural and organic hemp
products that provide a full spectrum of remedies for consumers across North
America suffering from multiple ailments,” said Carlos Frias, CEO, GL Brands.
“Our partnership with CB2 Insights will allow us to illustrate the effectiveness of our products across indications such as chronic pain, sleep disorders and anxiety.”
The project has already commenced and will continue through
patient recruitment, observations and trial close-out.